|

Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer

RECRUITINGSponsored by National Taiwan University Hospital
Actively Recruiting
SponsorNational Taiwan University Hospital
Started2021-03-01
Est. completion2025-12-31
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04814407

Summary

The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.

Eligibility

Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria:

* Subjects suspected or confirmed diagnosis of lung cancer.
* Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
* Non-cancer subjects: including healthy volunteers and chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
* Subjects age over 20.

Exclusion Criteria:

* Pregnancy.
* Subjects with HIV infection.
* Unable to or unwilling to give informed consent.

Conditions2

CancerLung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.